Medical device company LeMaitre Vascular (NASDAQ:LMAT) reported Q1 CY2025 results beating Wall Street’s revenue expectations , with sales up 12% year on year to $59.87 million. Guidance for next quarter’s revenue was optimistic at $62.5 million at the midpoint, 2.2% above analysts’ estimates. Its GAAP profit of $0.48 per share was 4.6% below analysts’ consensus estimates.

Is now the time to buy LeMaitre? Find out in our full research report .

LeMaitre (LMAT) Q1 CY2025 Highlights:

Chairman/CEO George LeMaitre said, “Q1 sales momentum allows us to increase our 2025 reported ($245mm) and organic (+13%) sales guidance, up from prior guidance of $239mm and 10%. $303mm of cash also provides strategic optionality.”

Company Overview

Founded in 1983 and named after a pioneering vascular surgeon, LeMaitre Vascular (NASDAQGM:LMAT) develops and manufactures specialized medical devices used by vascular surgeons to treat peripheral vascular disease and other circulatory conditions.

Sales Growth

A company’s long-term performance is an indicator of its overall quality. Any business can put up a good quarter or two, but many enduring ones grow for years. Thankfully, LeMaitre’s 13.7% annualized revenue growth over the last five years was solid. Its growth beat the average healthcare company and shows its offerings resonate with customers.

Long-term growth is the most important, but within healthcare, a half-decade historical view may miss new innovations or demand cycles. LeMaitre’s annualized revenue growth of 15.6% over the last two years is above its five-year trend, suggesting its demand was strong and recently accelerated.

We can dig further into the company’s sales dynamics by analyzing its organic revenue, which strips out one-time events like acquisitions and currency fluctuations that don’t accurately reflect its fundamentals. Over the last two years, LeMaitre’s organic revenue averaged 14.5% year-on-year growth. Because this number aligns with its normal revenue growth, we can see the company’s core operations (not acquisitions and divestitures) drove most of its results.

This quarter, LeMaitre reported year-on-year revenue growth of 12%, and its $59.87 million of revenue exceeded Wall Street’s estimates by 3.7%. Company management is currently guiding for a 11.9% year-on-year increase in sales next quarter.

Looking further ahead, sell-side analysts expect revenue to grow 8.9% over the next 12 months, a deceleration versus the last two years. Still, this projection is commendable and suggests the market is forecasting success for its products and services.

Unless you’ve been living under a rock, it should be obvious by now that generative AI is going to have a huge impact on how large corporations do business. While Nvidia and AMD are trading close to all-time highs, we prefer a lesser-known (but still profitable) stock benefiting from the rise of AI. .

Operating Margin

LeMaitre has been an efficient company over the last five years. It was one of the more profitable businesses in the healthcare sector, boasting an average operating margin of 21.3%.

Analyzing the trend in its profitability, LeMaitre’s operating margin of 23.4% for the trailing 12 months may be around the same as five years ago, but it has increased by 7.6 percentage points over the last two years.

This quarter, LeMaitre generated an operating profit margin of 21.1%, down 1.1 percentage points year on year. This reduction is quite minuscule and indicates the company’s overall cost structure has been relatively stable.

Earnings Per Share

We track the long-term change in earnings per share (EPS) for the same reason as long-term revenue growth. Compared to revenue, however, EPS highlights whether a company’s growth is profitable.

LeMaitre’s EPS grew at an astounding 18.1% compounded annual growth rate over the last five years, higher than its 13.7% annualized revenue growth. However, we take this with a grain of salt because its operating margin didn’t expand and it didn’t repurchase its shares, meaning the delta came from reduced interest expenses or taxes.

In Q1, LeMaitre reported EPS at $0.48, up from $0.44 in the same quarter last year. Despite growing year on year, this print missed analysts’ estimates, but we care more about long-term EPS growth than short-term movements. Over the next 12 months, Wall Street expects LeMaitre’s full-year EPS of $1.98 to grow 17.3%.

Key Takeaways from LeMaitre’s Q1 Results

It was great to see LeMaitre’s full-year revenue guidance top analysts’ expectations. We were also glad its organic revenue outperformed Wall Street’s estimates. On the other hand, its full-year EPS guidance missed significantly and its EPS guidance for next quarter fell short of Wall Street’s estimates. Overall, this was a softer quarter. The stock traded down 1.1% to $89.25 immediately following the results.

So should you invest in LeMaitre right now? We think that the latest quarter is just one piece of the longer-term business quality puzzle. Quality, when combined with valuation, can help determine if the stock is a buy. We cover that in our actionable full research report which you can read here, it’s free .